Teleradiology Solutions Celebrates its 10th Anniversary

Headquartered in Bangalore, Teleradiology Solutions (www.telradsol.com/) provides quality diagnosis to the world and much more.

Bangalore, India (PRWEB) February 24, 2012

Teleradiology Solutions, the #1 national teleradiology company in the United States, is happy to be celebrating the tenth anniversary of providing Teleradiology services to hospitals around the world. In a decade when a number of teleradiology vendors got sold or closed down, it is a matter of pride for TRS to still be standing and growing. It's special birthday gift was being awarded the title of "Best in KLAS" for Teleradiology Services in the USA 2011, by KLAS, a Utah-based research firm that specialises in monitoring healthcare vendors.

The company (www.telradsol.com) which started in a home office with 2 employees now has become a global group with radiologists based in Israel, USA, Europe and India. It covers over 150 hospitals in 20 countries globally. It recently started covering hospitals in Africa in Tanzania, Nigeria and Djibouti.

In 2005, the TRS became the first healthcare organisation outside Singapore to be accredited by the Ministry of Health of Singapore. In the same year it became one among the first teleradiology companies to be accredited by The Joint Commission, a U.S.-based organisation that accredits healthcare facilities. The Bangalore based company is growing and was showcased to US President Barack Obama during his visit to India in November 2010 as an example of innovation in action.

TRS not only provides teleradiology but is also involved in several other activities from training radiologists (www.radguru.net), to enabling teleradiology by other Radiologists/doctors by developing and marketing RadSpa, a new generation teleradiology workflow (http://teleradtech.com/), to helping poor patients in Asia get access to high quality diagnostics (www.teleradfoundation.org). The multispeciality clinic set up by it-RxDx (www.rxdx.in) uses Cisco's HealthPresence and provides telemedicine to poor patients living in villages in Raichur, located in North Karnataka in India. TRS has also become the managed service provider for Cisco's telemedicine in India in 2012.

Teleradiology Solutions is a company with a difference. It has evolved from being a pure nighthawk US teleradiology group to being at the forefront of several innovative technology and healthcare initiatives. For the coming decade, TRS aims at adhering to its new title -"Best in Klas" , innovating continuously, reaching needy patients around the world and widening its scope globally to include all facets of technology and health – teleradiology, telecardiology, tele-medical e-teaching, telemedicine and more.

Original PRWeb release

Read more

Virtual Microscopy – Real Regulations

 

Nice read by Dr. Stacey Mills over at Pathology Network (Pⁿ Blog). A recognized expert in surgical pathology and director of such at the University of Virginia, he writes, "It seems somewhat surprising, at least to me, that a technique based on standard light microscopy, with microscopes being essentially unregulated, Class I devices, should be given the "highest risk" class III rating." Vendors will have to speak to this at upcoming USCAP meeting.  I hope the word "surprise" is not in their vocabulary given statements made on this topic back at the FDA panel meeting in 2009 and inviting the FDA back to Pathology Visions for guidance on the subject.

The lead article in the January 2012 issue of CAP Today addresses the pending FDA regulation of whole slide imagers (WSI's). The FDA has concluded dthat these devices are "Class III" medical devices, and as such are subject to considerable federal regulation (compared to Class I and II devices).  Depending on your perspective, this is either a good thing for patient safety or the death knell for rapid development, certification and deployment of these devices in the United States, with many companies looking elsewhere for testing and validation).

 

By way of quick review, Class I devices are lowest risk and require no pre-market notification.  Your light microscope is, believe it or not, classified as a Class I device.  Class II devices are considered "moderate risk" and are usually based on modifications of prior approved devices or techniques.  Class III devices are considered "highest risk" and such devices require premarket FDA approval, quality controls, etc. Automated cytology screeners, for example, are Class III devices. The FDA has said that WSI's belong in this category as well.

 

It seems somewhat surprising, at least to me, that a technique based on standard light microscopy, with microscopes being essentially unregulated, Class I devices, should be given the "highest risk" Class III rating.  Although the rationale for that decision may be difficult to fathom, it has, in fact, been made and is highly unlikely to be reversed.

The fact that the FDA has even been reviewing WSI's and has decided to regulate them as "highest risk" Class III devices, may come as a surprise to most end-user pathologists since the topic of regulation is understandably not a major one at trade shows where vendors try to sell these devices.  It certainly isn't a topic the vendors themselves are likely to bring up, at least until now.

 

Although the FDA has been less than specific in discussing their thinking, they have indicated that they have concerns about image quality when compared to standard light microscopy, and the effect of navigating on a computer screen v. moving a slide on a microscope.  It is even unclear whether WSI's might be approved for a certain TYPE of specimen or group of diagnoses and not for other types or groups.  Might it be approved for small core biopsies and not for big tissue blocks?  Might it not be approved for hematologic malignancies, where the diagnosis often requires viewing large areas at relatively high magnification, something that is more difficult with a WSI?  At this point, no one knows.  Clinical trials comparing the accuracy of WSI's v. traditional microscopy will be difficult to construct and time consuming to perform, but will likely provide the data to answer these questions.

 

Given the FDA's pace of action in regard to other issues, it's now expected that it may take up to five years for the first devices to be approved in the United States, with Aperio likely to be among the first.  Some companies will most likely concentrate their efforts in Europe where the approval process (and subsequent sales) are likely to be much more rapid.

 

There are many unanswered questions at this early juncture, but it does seem clear that buying and using a WSI for clinical (not research) diagnosis would not be a prudent move at this point in time.  If you are currently using a WSI for primary clinical diagnosis, you had better have "state of the art" (whatever that is!) validation policies in effect, and even then your CLIA or CAP inspection is likely to be problematic.   Even when these instruments gain approval, their use for diagnosis at a distance will fall under the highly diverse state laws regarding telemedicine.  A topic I covered in one of my early blogs, "Down the Telepathology Rabbit Hole."

Published: 2/27/2012

Read more…

 

 

Stacey E. Mills, MD, a graduate of University of Virginia (UVA) and the UVA Medical Center, has authored nearly 230 articles, 20+ books, atlases and monographs—including the renowned Sternberg's Diagnostic Surgical Pathology. He has been a practicing Professor and Staff Pathologist at UVA for 30+ years and is Director of Surgical Pathology and Cytopathology. His clinical specialty is general surgical pathology with emphasis on neoplasms and neoplasm-like lesions. Dr. Mills is also Editor-in-Chief of The American Journal of Surgical Pathology.

 

Ventana Obtains FDA Clearance for Ki-67 Image Analysis

TUCSON, Ariz., Feb. 27, 2012 /PRNewswire/ – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Ki-67 (30-9) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software. Ventana is currently the only company offering an FDA cleared Ki-67 image analysis algorithm for determining Ki-67 expression levels in breast cancer patients.

The Ki-67 protein is known to be an excellent marker for cellular proliferation. The Ki-67 (30-9) application may assist pathologists in achieving objective and consistent Ki-67 interpretation and can provide quantitative results for images with hundreds or thousands of cells.

When the VENTANA Ki-67 (30-9) algorithm is used with the VENTANA CONFIRM anti-Ki-67 (30-9) Rabbit Monoclonal Primary antibody, it may be used as an aid in the assessment of Ki-67 status in breast cancer patients but is not the sole basis for treatment. The 510(k) clearance covers all components of the VENTANA workflow solution used together including the company's BenchMark slide stainer, Ki-67 (30-9) clone, detection systems, slide scanner and image management software.

"Ventana is the only company to offer a 510(k) cleared Ki-67 image analysis solution to pathologists today," said Dr. Steve Burnell, Vice President, Ventana Digital Pathology and Workflow. "This most recent addition to our digital pathology portfolio demonstrates our continued commitment to our customers by providing them with the most advanced clinical pathology workflow solutions available to support the highest standards of patient care."

Ventana also received FDA clearance for the digital read application that allows the pathologist to interpret Ki-67 (30-9) stained slides as images on a computer monitor with the VENTANA iScan Coreo Au scanner and Virtuoso software.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.

SOURCE Ventana Medical Systems, Inc.

 

Web applications and cloud hosting bring new affordable options to Digital Pathology

Web applications and cloud hosting bring new affordable options to Digital Pathology

Tissue Imaging is ready to go digital. In the last decade technology advances in hardware, computing, networking as well as declining storage prices have made storing and handling Whole Slide Images technically viable. The advantages of digital imaging are apparent and market size for pathology is significant, so a flock of companies from pioneers like Aperio and BioImagene, to established players like Leica, Zeiss, Olympus, Phillips and GE got busy working on innovative digital solutions for pathologists.

Today they have solutions that work well, but with the technical problem solved, the economic problem remains for typical pathology lab.  The Digital Pathology package usually includes a slide scanner, an image server and  software for handling and viewing digital slides, and will cost upwards of $150K for a typical installation. This price tag may be attainable for a large hospital chain with capital budgets and IT staff, but 80% of US pathology labs are small business employing staff of 10 people or less.  They are service providers that charge “by the drink” and have no capital budgets or IT support.  They cannot justify large IT investments or technical support staff.

For those who spent their careers in IT, this looks all too familiar: remember those old enterprise IT systems? If you wanted to have company email, share calendar and access your files remotely on the same server, you would have to spend hundreds of thousands of dollars on servers, software and IT support.  That is until cloud and web applications came along.  Now any small business can get big business IT for affordable monthly rate as long as it is connected to the internet, and every large tech company from Cisco to Microsoft is working hard to package their technology offerings for small businesses.

Serving the small business market economically is the inevitable next step and a challenge for Digital Pathology vendors. Number of industry innovators like Mikroscan, DigiPath, Objective Imaging, ViewsIQ and others are pushing technology envelope trying to bring the cost of equipment within the affordability range for a typical lab. They manage to bring hardware price under $30K. Yet, there is another challenge to overcome: small businesses have “0-0-0” expectation from technology. That means zero installation effort, zero learning curve and zero support. They need technology that “just works” and expect vendors to deliver it. The logical solution: cloud hosting and web applications. If done right, cloud software and web applications can bring the same benefits to pathology labs as they did to other businesses in other areas.

Houston-based software company, Smart Imaging Technologies aspires to bring cloud computing and web applications for whole slide imaging to Digital Pathology with software called Simagis Live. The company experience offers insights for those who are considering whole slide imaging in the cloud:

Upload. Once you move imaging server from the local network, uploading digital slides becomes a critical issue.  Traditional remote upload methods like FTP or WebDav do not work well for large image files; they drop data packets and take forever to complete the job. Smart Imaging had to develop special Turbo Upload Utility that can take Whole Slide Image or folder with image tiles and move it to remote server at blazing speed of 1.5 GB/ minute on high-speed internet connection, all with just 3 mouse clicks, right from the web browser. 

Access and Sharing. Small businesses do not conform to unified corporate IT policies. They use variety of computers, operating systems and browsers. So, the web image browser should “just work” across all computers, operating systems and browsers too, period. And don’t forget tablets! “Just works” means nothing to download, install or update before you can view digital slide online, be it on Windows, Mac, iPad, or Android tablet. Sharing and collaboration process in general should be both easy and secure. Users can invite collaborators and share digital slides in a few clicks, but also they should be able to separate shared and private images and revoke access at any time.

Integration. This issue is absolutely critical to success. In order to meet “0-0-0” expectation, the software should work seamlessly with the imaging hardware, making connections and handling images behind the scenes.  Simagis Live software, for example, includes nifty integration feature called “MicroPlug”.  It adds additional menu option “Save and Share” to imaging device software. When user clicks it, the digital slide is saved to disk and uploaded to user workspace on cloud server at the same time, automatically behind the scenes. The Company does not mind if an imaging device manufacturer puts custom branding on top of the software, in fact it encourages OEM and custom branding solutions as they deliver the most cohesive experience to the end user.  

Business Model and Pricing. Software technology vendors have to structure their offeringsso that they are paid the same way that their clients are paid and make money when their clients make money. They have to give customers no-obligation trials and free-tier service to try the new technology. Cloud software and web applications can provide that flexibility. In the case of Simagis Live, anybody can sign up for free service and get 2GB of space on public application server. If they like the experience, they can get additional space, rent private cloud server or install software on-site.  Clients can pay for only what they, by month or by image, with no upfront capital investments, long-term commitments, installation or IT costs.

In the coming years tissue imaging will follow the path of other imaging modalities like X-ray, CT and MRI and turn digital.  Web applications hold a lot of promise for Digital Pathology and Tissue Diagnostics.  Cloud software can make digital solutions affordable and universally accessible and we should see a lot of interesting developments in this area in the near future. 

 

Webinar: PathXL Tutor – Build a Microscopy Course

PathXL^TM Tutor: Digital Pathology Software for Education and Training

7th March 2012, 4.15pmGMT / 11.15amEST / 8.15amPST / 5.15pmCET

PathXL^TM Tutor allows users to create and manage digital slides and other content, publish online, share and view from anywhere in the world. 

Customers include The London Deanery, The Pathological Society of Great Britain & Ireland, University of Giessen, Royal Liverpool University Hospital and Queen's University Belfast.

Guest Speaker

Dr Stephen McCullough, Queen's University Belfast 

Why Attend

Learn how you can build online teaching modules for large groups of students and trainees, incorporating virtual slides, X-ray images, gross images and other multimedia. Test students and trainees using PathXL Online Test. 

No Digital Scanner? No problem! We have virtual slide catalogues covering a wide range of human and animal pathology, histology and cytology. The digital slides can be pre-loaded to your account. This means you can immediately start to build modules and use the pre-loaded slides as cases.

Click here to register

Digital Health NOW Spotlight Report: The Evolving Field of Digital Pathology

Research and Markets has announced the addition of the "Digital Health NOW Spotlight Report: The Evolving Field of Digital Pathology" report to their offering.

"Digital pathology is a disruptive technology; however, the consensus is that digital pathology is clearly our future. This iteration of Branham's Digital Health NOW Spotlight report takes a look at the emerging Digital Pathology market segment in health care. The report provides an overview and a general understanding of Digital Pathology rather than a detailed discussion of underlying technologies and vendors.

Digital pathology is rapidly gaining momentum as a proven and essential technology that is helping to reduce laboratory expenses, improve operational efficiency, enhance productivity and improve treatment decisions and patient care. It is used worldwide in drug development, reference lab, hospital, and academic medical centre settings. Applications include education, research, image analysis, archival and retrieval, LIS/LIMS integration, secondary consultations and virtual slide sharing. However, widespread adoption of digital pathology has been hindered not only by cost and technical factors but also largely by the mind set of technophobic pathologists.

Key Topics Covered:

What is Digital Pathology?

• Steps in Digital Pathology
• Scanning
• Quantitative Analysis and Computer-Assisted Image Data Mining
• Pathology Image Management and Storage

Benefits of Digital Pathology

• Dramatic Reduction in Misdiagnosis
• Remote Diagnosis and Support
• Educational Benefits

Market Trends

• Evolving Market
• Validation is Still Incomplete
• Archival and Retrieval Systems
• Regulatory Challenges
• Sluggish Growth
• Lack of Standards
• Telepathology
• Vendor Landscape

Final Thoughts

For more information visit: 

 http://www.researchandmarkets.com/research/548166/digital_health_now

 

 

Visiopharm Introduces APPsolute Digital Pathology

Cloud computing and models using software as a service are increasingly being used on a "per use" or "per case" basis as similar stories related to cloud computing on this blog have appeared. 

It is getting increasingly harder to talk about software with folks without being asked "Is there an app for that?"  The reasons for this are many – lower cost, ease of use, minimal development needed and ready "out of the box" as well as potentially increased portability on small screen mobile devices, tablets and pads.

Now comes word from Visiopharm their entrance into this space with some patent pending technology to facilitate image analysis with free trial, low cost and lowered upfront costs to implement software locally and maintain.

 

For the clinical market, "per-click" models have been attempted on the hardware side in the past.  These models may create a

disincentive to use versus a larger initial investment as folks get charged per case, per slide or per view.  For software such as image analysis, however, this model makes a lot of sense.  Use what you need when you need it that is proven and reliable from a library of tried and true algorithms.  

If you need to customize, you can create on demand with lower cost, risk and demonstration of performance as you need it.

Dr. Grunkin's quote below pretty much sums this up by lowering many barriers to entry.

For more information on this new offering leverage hosted computing and per analysis offering, check out Visiopharm's webinar mentioned at the end of the below press release and their booth at the upcoming USCAP meeting.

APPsolute Digital Pathology offers a novel approach to Quantitative Digital Pathology. Powered by CloudAnalysis and the APPCenter; currently featuring over 25 ready-to-use Analysis Protocol Packages (APPs).

APPsolute Digital Pathology is a novel approach to Quantitative Digital Pathology (QDP); costs are reduced, the learning curve is minimized, and the common risks of adoption are eliminated. The Visiopharm APPCenter provides access to a library of solutions that are ready-to-run and can be used with minimum training. Analysis Protocol Packages (APPs) can be tested free of charge before investing, productivity is achieved immediately, the upfront costs are low, and solutions can be scaled to fit customer needs.

A Pay-As-You-Go Solution: Low upfront costs

CloudAnalysis and APPs provide a low cost, easy to budget solution for customers who need access to sophisticated image analysis capabilities for a specific amount of time. Whether it is a week, a month, or longer you only pay for analysis when you need it.

Michael Grunkin, PhD, President of Visiopharm, stated "Currently, the cost structure of commercially available deployed Quantitative Digital Pathology solutions prevents the majority of researchers from benefitting from this increasingly important technology. This has to change. With our CloudAnalysis the upfront investment can be reduced to a fraction of any existing deployed solution. With CloudAnalysis there is always access to the most recent software version, studies can be run from anywhere, and technical deployment issues are eliminated."

The patent pending APPCenter provides customers with easy access to an extensive library of ready-to-run APPs. Each APP includes detailed descriptions, references to scientific literature, illustrated examples, webinars, and more. There is no need to become an expert in image analysis; APPs are created and validated in collaboration between experts in the field and Visiopharm’s application scientists and programmers.

Customers try an APP free of charge, before investing, to make sure that 1) the APP is working according to specifications, 2) the APP provides useful results, and 3) the APP can be understood and operated.

APPs are purchased for a low fixed cost, are yours to keep, and will work with both Visiopharm’s DeployedAnalysis and CloudAnalysis solutions. Custom APPs can be developed upon request, at a fixed known cost, and are also risk free with a complimentary trial.

"In a research project involving 300 patients, we worked with Visiopharm’s Image Analysis APPs developed for five different biomarkers. We could work seamlessly on the cloud, we were productive within an hour or two of training, and were able to complete and review the analysis of 5 x 300 tissue specimens in less than a week. The results we achieved were at least as good as manual scoring, and in several cases significantly better. The speed, convenience, and cost structure offered by CloudAnalysis and Image APPs makes Quantitative Digital Pathology an efficient, affordable, and attractive research tool", says Dr. Lars D. Andersen, Associate Professor, Group Leader, Center for Molecular Clinical Cancer Research, Department of Molecular Medicine (MOMA).

Built on leading technology

CloudAnalysis provides instant access from work, home, or from anywhere to the complete suite of Visiopharm software solutions; including advanced image analysis and stereology. Simply log in to your secure account and start to analyze your slides locally or in the cloud.

CloudAnalysis is built upon proven Whole Slide image analysis technology. Johan Doré, CTO at Visiopharm says, "Our solutions have been stress-tested over the last 10 years in the most demanding environments when it comes to capabilities, automation, and throughput. The feedback we consistently get from the world’s most experienced and sophisticated Digital Pathology users is, that we provide solutions with a lower learning curve, lower cost of ownership, by far the lowest computational costs, while providing high quality results."

Visit Visiopharm’s new website at http://www.visiopharm.com to learn more about APPsolute Digital Pathology and [register] for an introductory webinar on March 14, 2012 at 11 AM EST titled “Squaring the Circle of Quantitative Digital Pathology: instant implementation, while increasing productivity and achieving a return on investment."  In this webinar Visiopharm will demonstrate this new generation of software for Quantitative Digital Pathology with a flexible, affordable method of delivery in the Cloud.

About Visiopharm

Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 300 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.

Source: Visiopharm

Attend APF’s Spring Conference Next Week

American Pathology Foundation's 

2012 Spring Conference   

"Charting a New Course for Pathology; 

Navigation and Leadership In Turbulent Times" 

February 29 – March 2, 2012, Marriott Marquis, San Diego

LAST WEEK TO REGISTER! 

 

Make plans to join the American Pathology Foundation next week in San Diego, CA for our 2012 Spring Conference.  Attendees can look forward to three full days of informative sessions on best practices in the business of pathology and plenty of practical, "take home" ideas for better managing their time and resources.

 

APF conferences set the standard for pathology business and management education.  Our programs provide ample opportunities for you to collaborate and share experiences  with your colleagues.  The Spring Program has been carefully crafted to include the most timely topics and knowledgeable speakers to help you address critical practice management issues and is designated for 20.5 AMA PRA Category 1 Credits. 

 

In light of recent regulatory changes - YOU WON'T WANT TO MISS -these valuable sessions that will help you protect your practice, improve your bottom line and prepare for the future.

 

2012 Spring Conference Speakers & Topics Include:

• Navigating a Perfect Storm in Pathology – George Lundberg, MD
• Sink or Swim with Accountable Care Organizations -James Crawford, MD, PhD
• Key Compliance and Regulatory Issues Update  – Rick Cooper, Esq.
• 2012 Coding Issues Update – Dennis Padget, MBA, CPA, FHFMA
• Ensuring the Delivery of Vendor Obligations – Eric Carbonneau, John Allen, MBA
• LIS Implementation in Academic Health Systems-Joe Rondinelli, Raj Dash, MD
• Avoiding Common Lab Inspection Issues – Gerald Hoeltge, MD
• Improving Quality in CP/AP-LEAN Production Systems-Richard Zarbo,MD
• Leadership Development for Today and Tomorrow – CPT. Mark Brouker
• Choose Your Crew-Leadership Culture Drives Performance- Larry Siedlick, CEO
• 2012 Pathology Legal and Risk Management Update – Jane Pine Wood, Esq.
• PAP vs HPV Screening – What Does the Data Show? – Walter Kinney, MD
• Implementing New Molecular Tests and Controlling Costs- Samuel Caughron, MD
• Virtual Pathology -What is on the Horizon? -Gary Tearney, MD, PhD
• Creating Pathology Reports that Market Your Practice – Eric Glassy, MD

For online conference registration visit: www.apfconnect.org

 

You may also register over the phone by calling the 

APF National Office toll-free at: 877-993-9935, ext. 202  

 

             Reserve your room at the Marriott Marquis San Diego

            Contact hotel reservations toll-free at:  1-800-266-9432

 

Corista inks deal with MGH and Partners Healthcare

Corista to provide platform for Massachusetts General Hospital's Pathology Network

The Massachusetts General Hospital Pathology Service has chosen Corista's Digital Image Management Platform (DP3) to support its goal of providing clinical review of pathology cases with a digital platform. This new capability will allow MGH clinical experts to extend their reach to remote patients and their physicians for second opinions in real time.

"Recent technological advances have enabled immediate and widespread access to highly specific pathology expertise, speeding up both diagnosis and the start of treatment," said David Wilbur, MD, Director , Clinical Imaging -Pathology Services at MGH and Professor of Pathology at Harvard Medical School. "The key is having an image-centric platform that provides access together with the tools needed to respond and interact with multiple systems in the community."

 

Corista’s CEO, Elizabth Wingard said , "We’re pleased to be working with MGH and Partners Healthcare to extend the reach of the hospital’s expertise in pathology to physicians and patients in communities near and far. The Corista platform provides an intuitive case management dashboard that manages workflow and patient cases with digital images, and which can be integrated with existing hospital information systems," Wingard said. "In accessing specialists online and getting an immediate response, remote patients and hospitals can improve patient care with expertise that would have been delayed by days using couriers and FedEx. Eliminating the delay improves the patient’s care by enabling providers to initiate the appropriate treatment plan immediately."

 

Corista provides Pathologists with a single point of access to read and manipulate patient images with an extensive toolset for analysis, collaboration, diagnosis and report generation. With Corista's platform, MGH will be able to improve the process and quality of pathology medicine while extending real time clinical support for remote patients. 

About Corista

Since 2005, Corista has been developing its image-based processing software and proprietary browser-based software platform.  The patent-pending platform, DP3, provides a comprehensive solution for pathology practices that includes: a universal viewer that reads images from any whole slide imaging platform; secure local and remote image viewing and navigation, image management, on-demand colleague consultation, annotation, measurement  diagnoses; notifications to physicians of new cases or consults to be reviewed, and a centralized Physician Dashboard integrating in-house and remote patient cases into a single view for physicians. DP3 can integrate with existing hospital information systems, is hardware agnostic and supports a complete range of physician devices including high resolution monitors, tablets and touchscreens. 

 

Full size image

Source: Corista

 

Aurora to DICOMize Digital Pathology Images for Inclusion in PACS

Exciting news from Aurora Interactive mentioning inclusion of a DICOMizer within their functionality adding another needed piece to integration of pathology images into the PACS and electronic health record (EHR).

Aurora Interactive is including this new functionality in its mScope suite of products to allow a better integration of digital pathology images with radiology images and to simplify the inclusion of digital pathology images in the electronic health record (EHR)

MONTREAL, QUEBEC, CANADA- FEBRUARY 22, 2012 – Aurora Interactive announced today that it has added a DICOMizer to its mScope digital pathology product.  This tool will make the inclusion of report images in the hospital PACS possible which will allow the inclusion of these images in the electronic health record (EHR) where the PACS and the EHR are integrated.

“Aurora continues to reinforce its commitment to universality, interoperability, our client’s strategic flexibility and service. We believe in supporting our client’s in their efforts to deliver pathology diagnosis information to all diagnostic stakeholders through whatever means they choose.” stated Pierre Le Fèvre, President and Chief Executive Officer, Aurora Interactive.

About Aurora Interactive Ltd.

Aurora Interactive has developed the leading web based software platform (mScope) for simplification, productivity and ease of communications.  mScope’s Universal Web Viewer has collaborative tools to view medical slides and images anytime, anywhere, regardless of file format.  The software has four applications to aid digital pathology web based communications needs: mScope Education, mScope Clinical, mScope Research and mScope Universal Viewer. Aurora’s mission is to improve patient outcomes and help members of the medical community achieve their full potential by eliminating the learning, diagnostic and collaborative restrictions imposed by time and space. www.aurorainteractive.com